| Vazegepant HCl |
Vazegepant HCl |
1414976-20-7 |
| CC-90001 |
CC90001 |
1403859-14-2 |
| Aducanumab |
阿杜那单抗 |
1384260-65-4 |
| SOTA-008 |
SOTA-008 |
1384242-55-0 |
| (R)-N-(3-(2-methoxy-6-methylpyridin-3-yl)-1H-pyrazol-5-yl)-6-(piperidin-3-yloxy)pyrazin-2-amine |
LY2880070 |
1375637-35-6 |
| XD14 |
CS-2672 |
1370888-71-3 |
| 1369768-29-5 |
1369768-29-5 |
1369768-29-5 |
| Cobimetinib Fumarate |
可美替尼 |
1369665-02-0 |
| 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoicacid |
化合物PF-05221304 |
1370448-25-1 |
| 4(1H)-Quinolinone, 8-chloro-2-[(2,4-dichlorophenyl)amino]-3-(3-methyl-1-oxobutyl)-5-nitro- |
JH-RE-06 |
1361227-90-8 |
| 1,3,2-Dioxaborolane, 2-(2-ethoxyethenyl)- 4,4,5,5-tetramethyl- |
1360111-87-0 |
1360111-87-0 |
| AVL 292 benzenesulfonate |
1360053-81-1 |
1360053-81-1 |
| 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylicacid |
浅黄色至白色固体 |
1359963-68-0 |
| AZ32 |
AZ32 |
1353002-02-4 |
| Obiltoxaximab |
Obiltoxaximab |
1351337-07-9 |
| TAI-1 |
TAI-1 |
1334921-03-7 |
| Ozagrel-015 |
奥扎格雷标准品015 |
1332370-00-9 |
| Erlotinib IMpurity C |
埃罗替尼杂质C |
1312937-41-9 |
| Carbamic acid,N-[(1S)-4-cyano-2,3-dihydro-1H-inden-1-yl]-N-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-, 1,1-dimethylethyl ester |
1306763-61-0 |
1306763-61-0 |
| Benzonitrile, 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)aMino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-Methylethoxy)- (HCl salt) |
OZANIMOD |
1306760-85-9 |
QQ
微信
